Novo Nordisk Wins EU Approval for FREHEMGO Haemophilia A Therapy

The European Commission granted marketing authorization for FREHEMGO (denecimig), a therapy for routine prophylaxis of bleeding episodes in adults and children with haemophilia A, with or without inhibitors.